Global Insulin Biosimilars Market Size,Forecast, Growth Trends and Competitive A

Posted by shriya on June 9th, 2021

Global Insulin Biosimilars Market Research Report: By Type (Rapid-acting biosimilars, Long-acting biosimilars, Premixed biosimilars) and By Indication (TYPE I DIABETES, TYPE II DIABETES) – Forecast to 2027

Market Highlights

A disease in which the body’s ability to produce or respond to the hormone insulin is impaired, resulting in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood is termed as diabetes. Biosimilar insulin is designed to be highly similar to the original, or reference, insulin product described in a patent. As patents for major branded insulin products start to expire, a number of biosimilar insulin are expected to launch in the coming years. According to MRFR analysis, the Global Insulin Biosimilars Market Size is expected to register a CAGR of 5.4% during the forecast period of 2020 to 2027 to reach USD 3.3 Billion by 2027.


The market, based on type, has been divided into rapid-acting biosimilars, long-acting biosimilars, and premixed biosimilars. The long-acting biosimilars are likely to hold maximum market share in the global insulin biosimilars market owing to its benefits in the treatment for diabetes. Pre-mixed insulins are pre-formulated combinations of rapid-acting and long-acting insulin; they provide an approximation of basal/bolus therapy with the advantage of fewer total injection.

Regional Analysis

The European insulin biosimilars market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The insulin biosimilars market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rising prevalence of diabetes and the expansion of healthcare facilities, the market in Asia-Pacific is expected to be the fastest-growing. The insulin biosimilars market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

Some of the key players in the global insulin biosimilars market are Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co., NOVO Nordisk A/S, Biocon, Merck & Co., Mylan N.V., Pfizer Inc., Sandoz, Fresenius Kabi, and others.

Browse More Details at:


Akash Anand

Market Research Future

+1 646 845 9312


Like it? Share it!


About the Author

Joined: May 18th, 2021
Articles Posted: 81

More by this author